EUVIMEDEUVIMED entdecken
Crossref

Discovery of a Novel p38α-MK2 Complex Inhibitor as a Potential Choice for Autoimmune Diseases

Donglin Fu, Zimo Yang iD, Xiangyu Jia, Tian Han, Long Han, Xiaobing Zhang, Yuanfeng Xia, Siqin Wang, Lei Jin, Zhilong Hu iD, Fanglong Yang

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.4c01925 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Donglin Fu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Chemical Pharmaceutical Research Center, Changchun GeneScience Pharmaceutical Co., Ltd., Shanghai 200120, P.R. China. Hauptthemen laut MEDLINE: Rats, Inbred Lew, Arthritis, Experimental, Mitogen-Activated Protein Kinase 14, Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: GeneScience Pharmaceutical Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The p38α-MK2 signaling axis plays an important role in the inflammatory response of cells. Here, we carried out a series of optimizations on CDD-450, aiming to enhance inhibition of the p38α-MK2 complex and improve pharmacokinetic properties. First, the magic F strategy was utilized to obtain compound 21, which displayed a 60-fold increase in tumor necrosis factor α inhibition and a 600-fold increase in interleukin-6 inhibition. Molecular dynamics simulations revealed insights into the binding mode of fluorinated molecules. Subsequently, introducing a methyl group and a fluorine group led to compound 36, which showed improved pharmacokinetic properties in rats and dogs. Evaluation in the Lewis rat adjuvant-induced arthritis model showed that compound 36 had a robust inflammation inhibitory effect and joint repair ability. Currently, compound 36 is being considered for preclinical development as a potential treatment for inflammatory diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Rats, Inbred LewArthritis, ExperimentalMitogen-Activated Protein Kinase 14Protein Serine-Threonine KinasesIntracellular Signaling Peptides and ProteinsAutoimmune DiseasesAnimalsDogsRatsHumansProtein Kinase InhibitorsStructure-Activity RelationshipMaleMolecular Dynamics SimulationDrug DiscoveryTumor Necrosis Factor-alphaInterleukin-6Molecular Docking SimulationMAP-Kinase-Activated Kinase 2Interleukin-6 Inhibitors

Substanzen

Mitogen-Activated Protein Kinase 14Protein Serine-Threonine KinasesIntracellular Signaling Peptides and ProteinsProtein Kinase InhibitorsTumor Necrosis Factor-alphaInterleukin-6MAP-Kinase-Activated Kinase 2Interleukin-6 Inhibitors

Autor:innen und Institutionen

  • Chemical Pharmaceutical Research Center, Changchun GeneScience Pharmaceutical Co., Ltd., Shanghai 200120, P.R. China.
  • Changchun GeneScience Pharmaceutical Co., Ltd., Shanghai 200120, P.R. China.

ORCID-Profile: Zimo Yang, Zhilong Hu

Förderung

  • GeneScience Pharmaceutical Co., Ltd.

Zitieren

APA

Fu, D., Yang, Z., Jia, X., Han, T., Han, L., Zhang, X., Xia, Y., Wang, S., Jin, L., Hu, Z., & Yang, F. (2025). Discovery of a Novel p38α-MK2 Complex Inhibitor as a Potential Choice for Autoimmune Diseases. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01925

Vancouver

Fu D, Yang Z, Jia X, Han T, Han L, Zhang X, et al. Discovery of a Novel p38α-MK2 Complex Inhibitor as a Potential Choice for Autoimmune Diseases. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c01925

BibTeX
@article{Fu2025,
  author = {Fu, Donglin and Yang, Zimo and Jia, Xiangyu and Han, Tian and Han, Long and Zhang, Xiaobing and Xia, Yuanfeng and Wang, Siqin and Jin, Lei and Hu, Zhilong and Yang, Fanglong},
  title = {Discovery of a Novel p38α-MK2 Complex Inhibitor as a Potential Choice for Autoimmune Diseases},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.4c01925}
}
Kostenlos starten →